Evaxion A/S (NASDAQ:EVAX) Announces Earnings Results

Evaxion A/S (NASDAQ:EVAX) posted its quarterly earnings data on Thursday. The company reported $0.73 earnings per share (EPS) for the quarter, Zacks reports.

Evaxion A/S Price Performance

EVAX traded up $0.12 during trading on Friday, hitting $6.38. The company’s stock had a trading volume of 283,364 shares, compared to its average volume of 566,439. The company has a quick ratio of 3.42, a current ratio of 3.42 and a debt-to-equity ratio of 1.73. The stock has a market capitalization of $40.32 million, a price-to-earnings ratio of -16.36 and a beta of 0.28. The firm’s 50 day moving average price is $4.92 and its two-hundred day moving average price is $3.28. Evaxion A/S has a 12 month low of $1.20 and a 12 month high of $13.15.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Tuesday, October 14th. Lake Street Capital boosted their price target on shares of Evaxion A/S from $6.00 to $11.00 and gave the company a “buy” rating in a report on Monday, October 20th. Edward Jones initiated coverage on shares of Evaxion A/S in a report on Thursday, October 30th. They set a “buy” rating and a $10.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Evaxion A/S in a research report on Monday, October 20th. Finally, Jones Trading raised shares of Evaxion A/S to a “strong-buy” rating in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Evaxion A/S currently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.